959. Relapsing Clostridium difficile Associated Disease Followed by a Registry and Fecal Microbiota Transplant Attitudes Questionnaire
Session: Poster Abstract Session: Clostridium difficile Infections: Treatment and Prevention
Friday, October 9, 2015
Room: Poster Hall
Background: Management of Clostridium difficile associated disease (CDAD) moving forward requires clear data delineating the treatment and outcomes related to current practices. With this critically ill population and the advent of new agents including fecal microbiota transplant (FMT), we must determine where these interventions shoud be utilized . CDAD registry data was previously reported after six months, and we now report our one-year follow-up of hospital acquired CDAD patients enrolled in the registry describing treatment, relapse, adjunctive therapy and attitudes toward FMT.

Methods: Prospective observational study in an 1100 bed academic community health system. Patient enrollment between 4/2013 and 4/2014 included  hospitalized patients >18 years, having a first episode CDAD, > 3 stools/24 hours and a positive stool assay . Patients were excluded if there were barriers to follow up or anticipated <6-month survival. Telephone interviews were  conducted weekly then monthly for 1 year to determine CDAD activity, wellness, and attitudes.

Results: 158 patients were enrolled, and 113 were followed for a full 12 months. The all- cause mortality was 16%. Initial treatment included vancomycin (V) 19%, metronidazole (M) 55%, and combination (VM) 24%. Rifaximin or fidaxomicin were used for only 2% of patients. Treatment with combination therapy was more common in moderate/severe disease than mild disease (28% vs. 13%). 43% of patients received probiotics at some point in care. Primary relapse rate was 20% (23/113), and of those, 22% (5/23) patients had a second relapse (overall 4%). Attitudes toward FMT were assessed in 92 of the 158 enrolled patients, and 52% (48/92) of patients would accept FMT if offered.

Conclusion: The use of combination vancomycin/metronidazole is high and increasingly used in the severe CDAD patient. Our primary relapse rate of 20% appears to fit prior studies; however, our secondary relapse rate of 22%(4% overall) is lower than expected. 4% of our CDAD population are candidates for FMT based on strict hospital criteria (2 relapses). A high percentage of CDAD patients (52%) would accept FMT as treatment if offered.

Alfred E. Bacon III, MD1, Danielle Mosby, MPH1, Claudine Jurkovitz, MD2, Bailey Ingraham Lopresto, MS2, Marci Drees, MD, MS1,2, Anand Panwalker, MD, FIDSA1 and Patty Mcgraw, RN, MS1, (1)Christiana Care Health System, Newark, DE, (2)Value Institute, Christiana Care Health System, Newark, DE


A. E. Bacon III, None

D. Mosby, None

C. Jurkovitz, None

B. Ingraham Lopresto, None

M. Drees, None

A. Panwalker, None

P. Mcgraw, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.